arrow
H

Héctor G. Pálmer

vall d'hebron institut d'oncologia (vhio)
H指数:33
被引数:5,643

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mucinous differentiation (MD) as predictor of response in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with BRAF inhibitors (BRAFi) combinations

黏液分化 (MD) 可作为BRAF抑制剂 (BRAFi) 联合治疗的BRAF-V600E突变转移性结直肠癌 (mCRC) 反应的预测因子

2023-10-010
OA
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer
2023-06-0117
OAAI
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR x LGR5 bispecific antibody with efficacy in epithelial tumors
2022-04-2570
OA
Integrated analysis of cell-free DNA (cfDNA) BRAF mutant allele fraction (MAF) and whole exome sequencing in BRAFV600E metastatic colorectal cancer (mCRC) treated with BRAF-antiEGFR plus /- MEK inhibitors
2021-07-019
OAAI
Use of patient-derived tumour organoids to identify acquired treatment resistance and determine optimal post-progression combinations in metastatic colorectal cancer
2020-09-010
OAAI
The EurOPDX Research Infrastructure: Supporting European and worldwide cancer research with patient-derived xenografts
2020-08-150
PRE
Pharmacological disruption of the Notch transcription factor complex
2020-06-2973
OAAI
Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas
2020-02-1432
OAAI
Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial
2020-01-038
OAAI
TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence
2018-08-0681
OA
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)

双重MET和ERBB抑制克服奥希替尼耐药的晚期非小细胞肺癌 (NSCLC) 的肿瘤内可塑性

2017-10-0160
OAAI